VYNE Therapeutics (VYNE) Competitors $2.50 -0.20 (-7.41%) Closing price 01/29/2025 04:00 PM EasternExtended Trading$2.58 +0.09 (+3.40%) As of 08:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VYNE vs. ARTV, NLTX, CKPT, SLN, CDTX, MNPR, IFRX, FTLF, ADAP, and PBYIShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Artiva Biotherapeutics (ARTV), Neoleukin Therapeutics (NLTX), Checkpoint Therapeutics (CKPT), Silence Therapeutics (SLN), Cidara Therapeutics (CDTX), Monopar Therapeutics (MNPR), InflaRx (IFRX), FitLife Brands (FTLF), Adaptimmune Therapeutics (ADAP), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Artiva Biotherapeutics Neoleukin Therapeutics Checkpoint Therapeutics Silence Therapeutics Cidara Therapeutics Monopar Therapeutics InflaRx FitLife Brands Adaptimmune Therapeutics Puma Biotechnology Artiva Biotherapeutics (NASDAQ:ARTV) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk. Do analysts rate ARTV or VYNE? Artiva Biotherapeutics presently has a consensus target price of $21.00, indicating a potential upside of 290.33%. VYNE Therapeutics has a consensus target price of $6.88, indicating a potential upside of 175.00%. Given Artiva Biotherapeutics' higher probable upside, equities analysts clearly believe Artiva Biotherapeutics is more favorable than VYNE Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ARTV or VYNE? VYNE Therapeutics received 24 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 66.00% of users gave VYNE Therapeutics an outperform vote. CompanyUnderperformOutperformArtiva BiotherapeuticsOutperform Votes9100.00% Underperform VotesNo VotesVYNE TherapeuticsOutperform Votes3366.00% Underperform Votes1734.00% Does the media refer more to ARTV or VYNE? In the previous week, Artiva Biotherapeutics had 4 more articles in the media than VYNE Therapeutics. MarketBeat recorded 6 mentions for Artiva Biotherapeutics and 2 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.26 beat Artiva Biotherapeutics' score of 0.96 indicating that VYNE Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VYNE Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ARTV or VYNE? Artiva Biotherapeutics has higher revenue and earnings than VYNE Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$2.60M50.24N/AN/AN/AVYNE Therapeutics$420K87.80-$28.45M-$0.86-2.91 Do institutionals & insiders hold more shares of ARTV or VYNE? 83.8% of VYNE Therapeutics shares are owned by institutional investors. 4.8% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ARTV or VYNE more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,896.55%. Artiva Biotherapeutics' return on equity of 0.00% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A N/A N/A VYNE Therapeutics -6,896.55%-43.73%-38.55% SummaryArtiva Biotherapeutics beats VYNE Therapeutics on 8 of the 13 factors compared between the two stocks. Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.12M$6.62B$5.47B$9.25BDividend YieldN/A2.96%5.36%3.98%P/E Ratio-2.914.8361.5913.72Price / Sales87.80339.911,252.1480.62Price / CashN/A65.0944.3037.67Price / Book0.395.215.054.66Net Income-$28.45M$154.35M$117.51M$224.41M7 Day Performance-6.37%0.33%0.83%-1.00%1 Month Performance-21.63%1.02%3.87%0.75%1 Year Performance39.66%7.68%25.86%18.03% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics3.621 of 5 stars$2.50-7.4%$6.88+175.0%+38.9%$40.12M$420,000.00-2.9130Positive NewsARTVArtiva BiotherapeuticsN/A$6.53-3.7%$21.00+221.6%N/A$158.61MN/A0.0081NLTXNeoleukin TherapeuticsN/A$16.60-5.8%N/A-51.2%$156.01MN/A-5.3490News CoverageHigh Trading VolumeCKPTCheckpoint Therapeutics3.6138 of 5 stars$3.18-4.5%$12.00+277.4%+42.7%$155.28M$100,000.00-1.7310Short Interest ↑Gap DownSLNSilence Therapeutics2.7103 of 5 stars$5.12+1.8%$57.20+1,017.2%-72.3%$153.24M$31.55M-3.26100Analyst ForecastNews CoverageHigh Trading VolumeCDTXCidara Therapeutics4.3522 of 5 stars$21.70+2.1%$32.20+48.4%+32.6%$152.99M$63.90M-0.8590Analyst ForecastShort Interest ↑News CoverageHigh Trading VolumeMNPRMonopar Therapeutics1.767 of 5 stars$28.54-6.4%$38.50+34.9%+2,055.6%$150.69MN/A-14.4910IFRXInflaRx2.4064 of 5 stars$2.54-0.4%$8.00+215.0%+30.2%$149.56M$70,000.00-2.3560Short Interest ↑FTLFFitLife Brands4.7651 of 5 stars$32.47+1.5%$40.00+23.2%+43.6%$149.36M$52.70M19.2120Short Interest ↓High Trading VolumeADAPAdaptimmune Therapeutics2.4058 of 5 stars$0.58-1.7%$2.79+380.7%-26.6%$148.39M$175.04M-2.64490Short Interest ↑PBYIPuma Biotechnology4.2334 of 5 stars$2.97-1.7%$7.00+135.7%-38.4%$145.79M$243.57M6.19200Analyst RevisionPositive News Related Companies and Tools Related Companies ARTV Competitors NLTX Competitors CKPT Competitors SLN Competitors CDTX Competitors MNPR Competitors IFRX Competitors FTLF Competitors ADAP Competitors PBYI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VYNE) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
